Comment
Author: Admin | 2025-04-28
To inclisiran: subcutaneous solution.MetabolicVery common (10% or more): Diabetes mellitus (up to 11.6%)Note: in Pooled Safety Analysis-Treatment Emergent AEsDiabetes mellitusInclisiran: n=212, 11.6%Placebo: n=207, 11.4%LocalCommon (1% to 10%): Injection site reactions (included injection site pain, injection site erythema, injection site rash)[Ref]Injection site reactions occurred in 8.2% of patients and included injection site reaction (3.1%), injection site pain (2.2%), injection site erythema (1.6%), and injection site rash (0.7%). These reactions were mild or moderate in severity, transient, and resolved without sequelae.[Ref]MusculoskeletalCommon (1% to 10%): Arthralgia, back pain, pain in extremity[Ref]GenitourinaryCommon (1% to 10%): Urinary tract infection[Ref]RespiratoryCommon (1% to 10%): Bronchitis, nasopharyngitis, cough, dyspnea[Ref]GastrointestinalCommon (1% to 10%): Diarrhea[Ref]Nervous systemCommon (1% to 10%): Dizziness, headacheCardiovascularCommon (1% to 10%): Angina pectorisImmunologicCommon (1% to 10%): Anti-drug antibodies[Ref]Frequently asked questionsWhat are PCSK9 Inhibitors and how do they work?What is the difference between Leqvio and Repatha?Can Leqvio be taken without a statin?Does Leqvio cause weight gain?What is the mechanism of action for Leqvio (inclisiran)?How is Leqvio injection administered?Is Leqvio FDA approved as a high cholesterol treatment?Who is the actor in the Leqvio commercial?How does Leqvio work in treating high cholesterol?Where can I find the Leqvio FDA package insert?References1. Product Information. Leqvio (inclisiran). Novartis Pharmaceuticals. 2022.Further informationAlways consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Some side effects may not be reported. You may report them to the FDA.Medical Disclaimer
Add Comment